TRDA Valuation

Entrada Therapeutics Inc

Add to Watchlist

Advanced Chart

5.520

+0.25(4.744%)1D

Overview
Forecast
Valuation
Earnings

TRDA Relative Valuation

TRDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRDA is overvalued; if below, it's undervalued.

Historical Valuation

Entrada Therapeutics Inc (TRDA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 16.22 is considered Overvalued compared with the five-year average of -17.10. The fair price of Entrada Therapeutics Inc (TRDA) is between 0.98 to 3.94 according to relative valuation methord. Compared to the current price of 5.52 USD , Entrada Therapeutics Inc is Overvalued By 40.26%.

Relative Value

Fair Zone

0.98-3.94

Current Price：5.52

40.26%

Overvalued

-1.21

Trailing

Forward

0.00

EV/EBITDA

Entrada Therapeutics Inc. (TRDA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.61. The thresholds are as follows: Strongly Undervalued below -13.04, Undervalued between -13.04 and -7.32, Fairly Valued between 4.11 and -7.32, Overvalued between 4.11 and 9.82, and Strongly Overvalued above 9.82. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.52

EV/EBIT

Entrada Therapeutics Inc. (TRDA) has a current EV/EBIT of 0.52. The 5-year average EV/EBIT is -1.43. The thresholds are as follows: Strongly Undervalued below -15.49, Undervalued between -15.49 and -8.46, Fairly Valued between 5.59 and -8.46, Overvalued between 5.59 and 12.62, and Strongly Overvalued above 12.62. The current Forward EV/EBIT of 0.52 falls within the Historic Trend Line -Fairly Valued range.

16.22

Entrada Therapeutics Inc. (TRDA) has a current PS of 16.22. The 5-year average PS is 6.27. The thresholds are as follows: Strongly Undervalued below -4.58, Undervalued between -4.58 and 0.84, Fairly Valued between 11.70 and 0.84, Overvalued between 11.70 and 17.12, and Strongly Overvalued above 17.12. The current Forward PS of 16.22 falls within the Overvalued range.

0.00

P/OCF

Entrada Therapeutics Inc. (TRDA) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.75. The thresholds are as follows: Strongly Undervalued below -16.39, Undervalued between -16.39 and -9.07, Fairly Valued between 5.58 and -9.07, Overvalued between 5.58 and 12.90, and Strongly Overvalued above 12.90. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Entrada Therapeutics Inc. (TRDA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Entrada Therapeutics Inc (TRDA) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 1.68 , the current P/B ratio is approximately -70.61% higher. Relative to its 5-year average P/B ratio of 1.48, the current P/B ratio is about -66.62% higher. Entrada Therapeutics Inc (TRDA) has a Forward Free Cash Flow (FCF) yield of approximately -67.55%. Compared to its 3-year average FCF yield of -1.65%, the current FCF yield is approximately 3999.63% lower. Relative to its 5-year average FCF yield of -5.50% , the current FCF yield is about 1128.31% lower.

0.49

P/B

Median3y

1.68

Median5y

1.48

-67.55

FCF Yield

Median3y

-1.65

Median5y

-5.50

Competitors Valuation Multiple

The average P/S ratio for TRDA's competitors is 9.59, providing a benchmark for relative valuation. Entrada Therapeutics Inc Corp (TRDA) exhibits a P/S ratio of 16.22, which is 69.20% above the industry average. Given its robust revenue growth of -97.94%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TRDA.O

Entrada Therapeutics Inc

Ventyx Biosciences Inc

Loss

201.80M

LYEL.O

Lyell Immunopharma Inc

Heron Therapeutics Inc

Voyager Therapeutics Inc

Contineum Therapeutics Inc

34.49

227.14M

Performance Decomposition

Market capitalization of TRDA decreased by 68.81% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.07 to -2.94.

The secondary factor is the Revenue Growth, contributed -97.94%to the performance.

Overall, the performance of TRDA in the past 1 year is driven by P/E Change. Which is more unsustainable.

-97.94%

94.69M → 1.95M

Revenue Growth

-3903.84%

58.11 → -2.21K

Margin Expansion

3932.97%

-0.07 → -2.94

P/E Change

-68.81%